Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis

被引:46
|
作者
Ansell, B. R. E. [1 ,2 ]
Dwyer, D. B. [1 ,2 ]
Wood, S. J. [1 ,2 ]
Bora, E. [1 ,2 ]
Brewer, W. J. [3 ]
Proffitt, T. M. [3 ]
Velakoulis, D. [1 ,2 ]
McGorry, P. D. [3 ]
Pantelis, C. [1 ,2 ]
机构
[1] Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Carlton, Vic, Australia
[2] Melbourne Hlth, Carlton, Vic, Australia
[3] Univ Melbourne, Orygen Youth Hlth Res Ctr, Parkville, Vic 3052, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Antipsychotics; cortical thickness; first-episode psychosis; first-generation; second-generation; GRAY-MATTER VOLUME; HUMAN CEREBRAL-CORTEX; ATYPICAL ANTIPSYCHOTICS; CHRONIC-SCHIZOPHRENIA; BIPOLAR DISORDER; GREY-MATTER; BLOOD-FLOW; BRAIN; ABNORMALITIES; DRUGS;
D O I
10.1017/S0033291714001652
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background. Whether there are differential effects of first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) on the brain is currently debated. Although some studies report that FGAs reduce grey matter more than SGAs, others do not, and research to date is limited by a focus on schizophrenia spectrum disorders. To address this limitation, this study investigated the effects of medication in patients being treated for first-episode schizophrenia or affective psychoses. Method. Cortical thickness was compared between 52 first-episode psychosis patients separated into diagnostic (i.e. schizophrenia or affective psychosis) and medication (i.e. FGA and SGA) subgroups. Patients in each group were also compared to age-and sex-matched healthy controls (n=28). A whole-brain cortical thickness interaction analysis of medication and diagnosis was then performed. Correlations between cortical thickness with antipsychotic dose and psychotic symptoms were examined. Results. The effects of medication and diagnosis did not interact, suggesting independent effects. Compared with controls, diagnostic differences were found in frontal, parietal and temporal regions. Decreased thickness in FGA-treated versus SGA-treated groups was found in a large frontoparietal region (p<0.001, corrected). Comparisons with healthy controls revealed decreased cortical thickness in the FGA group whereas the SGA group showed increases in addition to decreases. In FGA-treated patients cortical thinning was associated with higher negative symptoms whereas increased cortical thickness in the SGA-treated group was associated with lower positive symptoms. Conclusions. Our results suggest that FGA and SGA treatments have divergent effects on cortical thickness during the first episode of psychosis that are independent from changes due to illness.
引用
收藏
页码:515 / 527
页数:13
相关论文
共 50 条
  • [1] Divergent Effects of First- and Second-generation Antipsychotics on Cortical Thickness in First-episode Psychosis
    Dwyer, Dominic B.
    Ansell, Brendan R. E.
    Wood, Stephen J.
    Bora, Emre
    Brewer, Warrick
    Proffitt, Tina
    Velakoulis, Dennis
    McGorry, Patrick D.
    Pantelis, Christos
    [J]. BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 249S - 249S
  • [2] Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis
    Ikuta, Toshikazu
    Robinson, Delbert G.
    Gallego, Juan A.
    Peters, Bart D.
    Gruner, Patricia
    Kane, John
    John, Majnu
    Sevy, Serge
    Malhotra, Anil K.
    Szeszko, Philip R.
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 2014, 221 (02) : 127 - 134
  • [3] Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
    Zhang, Jian-Ping
    Gallego, Juan A.
    Robinson, Delbert G.
    Malhotra, Anil K.
    Kane, John M.
    Correll, Christoph U.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2013, 16 (06): : 1205 - 1218
  • [4] The effect of second-generation antipsychotics on basal ganglia and thalamus in first-episode psychosis patients
    Albacete, Auria
    Makowski, Carolina
    Chakravarty, M. Mallar
    Joober, Ridha
    Malla, Ashok K.
    Contreras, Fernando
    Menchon, Jose Manuel
    Lepage, Martin
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 (12) : 1408 - 1418
  • [5] A review of second-generation antipsychotic discontinuation in first-episode psychosis
    Miller, Brian J.
    [J]. JOURNAL OF PSYCHIATRIC PRACTICE, 2008, 14 (05) : 289 - 300
  • [6] Review: Specialist programmes and second-generation antipsychotics reduce relapse after first-episode psychosis
    Miller, Brian J.
    Crittenden, Krystle
    [J]. EVIDENCE-BASED MENTAL HEALTH, 2011, 14 (04) : 101 - 101
  • [7] Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review
    Salgueiro, Monika
    Segarra, Rafael
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2019, 34 (02) : 51 - 56
  • [8] No difference in extrapyramidal side effects between first-generation and second-generation antipsychotics
    Carnahan, Ryan
    [J]. EVIDENCE-BASED MENTAL HEALTH, 2012, 15 (04) : 91 - 91
  • [9] Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis
    Roosens, Laurence
    Neels, Hugo M.
    Sabbe, Bernard G.
    [J]. THERAPEUTIC DRUG MONITORING, 2019, 41 (02) : 252 - 253
  • [10] Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program
    Gardner, David M.
    Abidi, Sabina
    Ursuliak, Zenovia
    Morrison, Jason
    Teehan, Michael D.
    Tibbo, Philip G.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (06) : 715 - 718